Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nepafenac 0.3% for prevention and treatment of ocular inflammation and pain after cataract surgery
2010-019507-28Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Postoperative ocular inflammation, post-operative ocular pain and cataract comparing Nepafenac 0.3% with Placebo (2 arms). Primary endpoint: Clinical cure of ocular inflammation at day 14. Started Jul 2010; status: completed.
02
Drugs
nepafenac
03
Conditions
Postoperative ocular inflammationpost-operative ocular paincataract
Beyond the preview
Go deeper on 2010-019507-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019507-28.